You are here: Industry Insights > Major Depressive Disorder

News List

Relmada Announces Outcome of FDA Meeting for Major Depressive Disorder Treatment americanpharmaceuticalreview
June 02, 2020
Relmada Therapeutics announced the completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its development program of REL-1017 (dextromethadone) for the adjunctive treatment of major depressive disorder (MDD) patients.
Health Canada Approves Otsuka and Lundbeck's REXULTI (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder firstwordpharma
February 23, 2019
"Brexpiprazole, is a new option for patients with MDD who require augmentation therapy. Its unique mechanism of action and potential benefits will be a new source of optimism for patients suffering from Depression" said Dr. Diane McIntosh.
FDA advisors turn down Alkermes’ ALKS 5461 pharmatimes
November 05, 2018
Alkermes’ ALKS 5461 has been hit with a potential setback in the US after regulatory advisors failed to back its approval for major depressive disorder (MDD).
Allergan reports topline Phase II data supporting advancement of Botox for the treatment of MDD cphi-online
April 11, 2017
Botox is currently being studied as a potential treatment option for adult patients with moderate to severe MDD.